ArticleACS synthetic biology2019
Repurposing Protein Degradation for Optogenetic Modulation of Protein Activities.
Article in ACS synthetic biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 18 citations in OpenAlex.
- Design principles for optogenetic-based targeted protein degradation.Synthetic and systems biotechnology · 2026Review
- Dynamic Control of Cell Signaling with Optogenetic Modulation of Protein Abundance in Living Mammalian Cells.Methods in molecular biology (Clifton, N.J.) · 2026Article
- POT, an optogenetics-based endogenous protein degradation system.Communications biology · 2025Article
- Degradation bottlenecks and resource competition in transiently and stably engineered mammalian cells.Nature communications · 2025Article
- Photodegradable by Yellow-Orange Light degFusionRed Optogenetic Module with Autocatalytically Formed Chromophore.International journal of molecular sciences · 2023Article
- Optogenetics in bacteria - applications and opportunities.FEMS microbiology reviews · 2022Review
- Optogenetic approaches for understanding homeostatic and degenerative processes in Drosophila.Cellular and molecular life sciences : CMLS · 2021Review
- Steering Molecular Activity with Optogenetics: Recent Advances and Perspectives.Advanced biology · 2021Review
- Novel method for gain-of-function analyses in primary osteoclasts using a non-viral gene delivery system.Journal of bone and mineral metabolism · 2021Article
- A light way for nuclear cell biologists.Journal of biochemistry · 2021Review
- Engineering Photosensory Modules of Non-Opsin-Based Optogenetic Actuators.International journal of molecular sciences · 2020Review
- On the cutting edge: protease-based methods for sensing and controlling cell biology.Nature methods · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Non-neuronal optogenetic approaches empower precise regulation of protein dynamics in live cells but often require target-specific protein engineering. To address this challenge, we developed a generalizable light-modulated protein stabilization system (GLIMPSe) to control the intracellular protein level independent of its functionality. We applied GLIMPSe to control two distinct classes of proteins: mitogen-activated protein kinase phosphatase 3 (MKP3), a negative regulator of the extracellular signal-regulated kinase (ERK) pathway, and a constitutively active form of MEK (CA MEK), a positive regulator of the same pathway. Kinetics study showed that light-induced protein stabilization could be achieved within 30 min of blue light stimulation. GLIMPSe enables target-independent optogenetic control of protein activities and therefore minimizes the systematic variation embedded within different photoactivatable proteins. Overall, GLIMPSe promises to achieve light-mediated post-translational stabilization of a wide array of target proteins in live cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.